Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART (NILACH)

This study has been terminated.
(Withdrawal of IMP from the market. Data on risk-benefit ratio pending.)
Sponsor:
Collaborators:
University Hospital, Geneva
Swiss National Science Foundation
Fondation Ernest Boninchi
Swiss Heart Foundation
Information provided by (Responsible Party):
Calmy Alexandra, University Hospital, Geneva
ClinicalTrials.gov Identifier:
NCT01683656
First received: August 31, 2012
Last updated: March 14, 2013
Last verified: March 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: July 2014
  Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)